Pooled Results of Two Randomized Phase 3 Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

media

posted on 2021-02-03, 20:35 authored by Lawrence F. Eichenfield, Elaine Siegfried, Pearl Kwong, Mark McBride, Jayson Rieger, David Glover, Cynthia Willson, Matthew Davidson, Patrick Burnett, Melissa Olivadoti

The above video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).